Although we showed the ability of high EGF to predict outcome, a larger study using standardized treatment protocols with longer follow-up duration and repeated EGF measurements would be needed to assess the full benefit of EGF monitoring in the clinical management of LN. The gene discussed is EGF; the disease is lobular neoplasia.